Harrow Appoints Amir Shojaei as CSO to Enhance Eyecare Innovation and Development

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer, Strengthening Eyecare Innovation

Harrow, a leading North American eyecare pharmaceutical company, recently announces the appointment of Amir H. Shojaei, PharmD, PhD, as its new Chief Scientific Officer (CSO). Dr. Shojaei brings nearly three decades of experience in the life sciences, with a robust focus on clinical development and regulatory affairs, particularly within the ophthalmology sphere. His previous role as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics saw him spearheading innovative therapies for neovascular retinal disorders, positioning him as a key player in advancing eyecare solutions. This extensive background aligns well with Harrow’s commitment to enhancing accessibility and innovation in eyecare.

Dr. Shojaei's previous accomplishments include critical contributions to the FDA approval of Xiidra® in 2013, which marked a significant milestone in treating dry eye disease (DED). This landmark approval not only transformed the treatment landscape for DED but also paved the way for future innovations, including Harrow’s own VEVYE, launched last year. By leveraging his impressive expertise, Dr. Shojaei is positioned to lead Harrow through its next growth phase, focusing on developing cutting-edge biopharmaceutical products that address unmet needs in the eyecare market. CEO Mark L. Baum emphasizes the importance of Dr. Shojaei’s scientific and regulatory proficiency, noting that it is an ideal match for Harrow’s mission.

The transition comes as Harrow bids farewell to Dennis E. Saadeh, PharmD, who retires after nearly a decade of service. Saadeh has played a vital role in the company’s growth and the development of its market-leading compounded products, which have positively impacted millions of Americans. Baum acknowledges Saadeh’s contributions, highlighting his influence on both patient care and the company's overall success. With Dr. Shojaei at the helm of scientific development, Harrow anticipates an exciting new chapter that will not only advance its product pipeline but also enhance the quality of eyecare available to patients.

In other relevant news, Harrow continues to focus on expanding its portfolio of ophthalmic products and improving patient outcomes. The company’s innovative approach aims to position it as a frontrunner in the rapidly evolving eyecare pharmaceutical landscape, thereby meeting the increasing demand for effective treatments. Dr. Shojaei’s appointment is anticipated to further solidify Harrow’s role as a pioneer in eyecare solutions.